Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Usana Health Sciences (USNA) Short-Term Debt issuances (2016 - 2026)

Usana Health Sciences has reported Short-Term Debt issuances over the past 10 years, most recently at $4.0 million for Q2 2026.

  • Quarterly Short-Term Debt issuances changed N/A to $4.0 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $21.6 million through Apr 2026, down 6.7% year-over-year, with the annual reading at $17.6 million for FY2026, 25.7% down from the prior year.
  • Short-Term Debt issuances was $4.0 million for Q2 2026 at Usana Health Sciences, down from $16.0 million in the prior quarter.
  • Over five years, Short-Term Debt issuances peaked at $23.0 million in Q4 2024 and troughed at -$60.0 million in Q1 2022.
  • The 5-year median for Short-Term Debt issuances is $750000.0 (2023), against an average of -$167000.0.
  • The largest YoY upside for Short-Term Debt issuances was 2803.79% in 2024 against a maximum downside of 79.47% in 2024.
  • A 5-year view of Short-Term Debt issuances shows it stood at $500000.0 in 2022, then skyrocketed by 58.4% to $792000.0 in 2023, then soared by 2803.79% to $23.0 million in 2024, then crashed by 93.04% to $1.6 million in 2025, then surged by 150.0% to $4.0 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Short-Term Debt issuances are $4.0 million (Q2 2026), $16.0 million (Q1 2026), and $1.6 million (Q2 2025).